We attempted to characterize the cellular autofluorescence phenomenon of living HL-60 cells and to appraise its modifications under oxidative stress conditions induced by 1α,25(OH) 2 D 3 (VD 3 ) and its analog EB1089. Autofluorescence emission spectra of human promyelocytic HL-60 leukemic cells were monitored using laser scanning confocal microspectrofluorometry under UV excitation. Evaluation of reactive oxygen species (ROS) release was performed using the 2',7'-dichlorodihydrofluorescein diacetate (H 2 -DCFDA) staining and fluorescence emission measurement. VD 3 (1, 10, 100 nM) or EB1089 (0.1, 1 and 10 nM) induces a decrease in autofluorescence emission intensity that can be attributed to the oxidation of the coenzyme nicotinamide adenine dinucleotide (phosphate) NAD(P)H into NAD(P) + . A dose-dependent increase (p<0.05) in ROS release is observed in VD 3 -and EB1089-treated cells. As compared with VD 3 -or EB1089-treated cells, doxorubicin-VD 3 or doxorubicin-EB1089 treatments strongly decrease the autofluorescence intensity and induce a higher release of ROS (p<0.05). The association of antioxidants (N-acetyl cysteine, superoxide dismutase, catalase) with VD 3 or EB1089 induce a more limited autofluorescence decrease and a weaker ROS generation, as compared with VD 3 and EB1089 treated cells. In conclusion, the free radicals release, generated by VD 3 and EB1089, was associated with the decrease in autofluorescence emission and can be modulated by doxorubicin and antioxidants.
Introduction
The native cellular fluorescence, also called autofluorescence, has aroused a high interest to study the metabolic activity and the redox state of living tissue in various species (1). The autofluorescence emission spectra of living cells correspond to the superimposition of the fluorescence spectra from different endogenous fluorophores (collagen, elastin, tryptophan, reduced nicotinamide adenine dinucleotide (phosphate) NAD(P)H, FAD) (1-4). Autofluorescence spectra depend on these fluorophores concentrations and on the excitation wavelength (5) . For a 360 nm excitation, the mitochondrial coenzyme NAD(P)H has been identified as the main molecule responsible for autofluorescence (2) (3) (4) 6) and produces a 400-500 nm fluorescence emission. The fluorescence yield of the reduced form NAD(P)H is significantly higher than the oxidized form NAD + . This autofluorescence phenomenon would correspond to the NAD(P)H/NAD + ratio variations. A large number of studies have reported the efficacy of autofluorescence analysis to obtain diagnostic information in several pathological diseases including cancers (7-10).
Our previous studies have investigated the effect of oxidative stress on cellular autofluorescence process in K562 cell line under a 363 nm excitation wavelength (11) . We have demonstrated that an oxidative stress induces a weak change in autofluorescence emission spectra and a significant decrease in emission intensity. This change has been attributed to the oxidation of NAD(P)H into NAD + both inside and outside mitochondria. For example, a fluorescence intensity decrease (factor 2.5) in 500 µM H 2 O 2 -treated cells was reported. These previous results have allowed to better describe the different cytotoxic pathways borrowed by anticancer quinones. Redox cycling leading to oxidative stress has been proposed as one of the mechanisms by which different agents (Dox, menadione) exert their cytotoxicity in different cancer cells (12, 13) . Several agents including Dox are able to generate free radicals (14) and to cause important cellular damage particularly at the DNA level (15, 16) . In addition, we showed that an antioxidant agent glutathione (GSH) inhibited both the autofluorescence decrease and Dox-induced ROS generation, suggesting that the ROS release would be associated with the decrease in autofluorescence intensity, leading to a cytotoxic activity of Dox.
The hormonally metabolic active form of vitamin D, 1α,25(OH) 2 D 3 (VD 3 ) is well known for its role in the modulation of proliferation and differentiation of several normal and malignant cell types (17) . In fact, a significant number of in vitro studies have demonstrated that VD 3 inhibits cell growth and promotes cell differentiation in many tumor cells (breast, colon, prostate, glioma, pancreas, neuroblas-toma…) (18-20) . Moreover, VD 3 induces apoptosis in breast cancer cells (21) and decreases invasiveness of a number of different cell lines in vitro and tumor regression in vivo (20) . Non toxic doses of VD 3 could induce active cell death within oxidative stress mechanism, via generation and release of ROS in 23) . VD 3 enhances the susceptibility of breast cancer cells to Dox-induced oxidative damage (16). Among the different analogs of VD 3 , EB1089 was approximately 50 to 200 times more potent than VD 3 in most of cancer cells with respect to inhibition of cell proliferation (20) . In leukemic cells, the antiproliferative effect was accompanied by an increase in the expression of differentiation markers such as CD14 or CD11b (24). In breast cancer cells, EB1089 enhances the anti-proliferative and apoptotic effects of Dox (25). Vitamin D analogs interact with signaling pathways leading to active cell death in breast cancer cells (26). Antioxidant supplementation decreases oxidative DNA damage in human lymphocytes (27) .
In this report, the confocal microspectrofluorometry analysis of autofluorescence has been performed in human living cells, under a 363 nm excitation. Emission spectra of cellular autofluorescence were compared. We attempted to characterize the cellular autofluorescence phenomenon of HL-60 cells and to appraise its modifications under oxidative stress conditions induced by VD 3 , EB1089. These monocytic/granulocytic lineage inducing agents were associated or not with Dox and antioxidants in order to modulate the oxidative stress.
Materials and Methods

Cell Lines and Culture Conditions
Human promyelocytic HL-60 leukemic cells HL-60 cells, purchased from the American Type Culture Collection (Rockville, MD,USA) were grown in a 5% CO 2 atmosphere at 37 ºC in RPMI 1640 (1X) medium (Bio-Wittaker, France) with L-glutamin, supplemented with 15% fetal calf serum (FCS) (Gibco-BRL, UK). Cell growth and viability were assessed utilizing the trypan blue exclusion technique (Sigma, France). Cells were routinely examined for mycoplasma contamination.
Chemicals
Dox, used as hydrochloride, was prepared as 10 -3 M stock solutions (R. Bellon, France) in distilled water and stored at -20 ºC. Hydrogen peroxide (H 2 O 2 ) 3% in phosphate buffered saline (PBS) (Sigma, France) was prepared as 10 -3 M solution, stored at room temperature, in the dark. VD 3 was purchased from Sigma (France). EB1089 was generously provided by Dr Lise Binderup from Leo Pharmaceuticals Products (Ballerup, Denmark). VD 3 was diluted in absolute ethanol at 10 µM as stock solution. EB1089 were supplied as solution diluted in isopropanol (2-propanol) at 4 × 10 -3 M. Dilution was performed in absolute ethanol to give stock solutions of 100 µM. The aliquots of stock solutions from both compounds were stored at -20 ºC, protected from the light until use. As the final concentration of ethanol in the culture medium was 0.1%, and it had no effect on either cell growth or oxidative stress, the same volume of ethanol was added to serve as control culture.
Antioxidant Protection
N-acetyl cysteine (NAC), Superoxide dismutase (SOD) and Catalase (CAT) were purchased from Sigma (France). NAC was dissolved in phosphate buffered saline (PBS) 1X to form a 1 M stock solution and the pH was adjusted to 7.3 with sodium hydroxide solution. The enzymes SOD and CAT were dissolved in PBS 1X to get stock solutions at 10 5 U/ mL and 15 × 10 3 U/mL, respectively. All antioxidant agents were freshly prepared and added to the cell culture medium 1 hour before VD 3 or EB1089 incubation.
Laser Scanning Microspectrofluorometry
x y emission spectra from a confocal section within a living cell were recorded using a confocal laser scanning microspectrofluorometer (Jobin Yvon [Horiba group], France). As previously described (11), a conventional optical microscope (Olympus BH2) was equipped with a 100X water immersion objective lens (Olympus) which the numerical aperture is 1.3. This lens was corrected for axial chromatic aberrations so that both excitation and emission voxels were superposed. This allowed observation of the sample, focusing of a 5 µW laser beam emitting at 363 nm (Spectra Physics, France) and collection of the fluorescence emission in the 365-580 nm range through the same optics. The pinehole size was fixed to a diameter of 600 µm, which confers a resolution of 3 µm (z) and 1 × 1 µm 2 in (x, y). Each spectrum acquisition time is about one second. Scanning of a cell was performed with a motorized stage (Olympus) and 15 × 15 spectra were recorded. The fluorescence emission was spectrally dispersed with a diffraction grating, analyzed with an optical multi-channel CCD detector coupled to an image intensifier. A computer simultaneously performed the control of stage motions and spectral data storage.
UV Spectrophotometry
Cells were analyzed by spectrophotometry to appraise NAD(P)H variations during treatments. 5 × 10 6 cells in 1 mL of PBS at 20 ºC were disrupted by 5 × 10 sec pulse on ice (spaced by 10 sec pulse off), using a high intensity ultrasound processor Vibra cell 72412 (Fisher Bioblock Scientific, France). This instrument which can deliver a maximum electric power of 400 Watts was set to 160 Watts, i.e., 40% of the maximum power. After sonication, debris were removed by centrifugation at 12000 g in microtube eppendorf 1.5 mL safelock naturel (Dominique Dutscher S.A., France). The supernatants from different samples were finally collected and analyzed by a spectrophotometer at 260 nm and 340 nm wavelengths for optical densities (O.D.) acquisition.
Measurements of Intracellular Emission Spectra After Drug-treatment
HL-60 cells in exponential growth phase were incubated, at 2 x 10 5 /mL density in Petri dishes containing 2 mL RPMI medium, and different treatments were added during 72 hours: VD 3 (1, 10 or 100 nM) and EB1089 (0.1, 1 or 10 nM). Cells were washed free of drug and placed in a Petri dish containing RPMI without phenol red. Intracellular fluorescence of Dox does not interfere with autofluorescence, due to the weak absorbance of this compound in UV and the redshifted emission with autofluorescence. A treatment with NAC, CAT and SOD for 72 hours was assessed in HL-60 cells exposed or not to the different drugs.
Measurement of ROS Release by Fluorescence Spectroscopy
The 2',7'-dichlorodihydrofluorescein diacetate (H 2 -DCFDA) probe (Molecular Probes, France) allows us to detect ROS production in situ. The cell-permeant form, H 2 -DCFDA diffuses rapidly through the cell membrane and then is hydrolyzed by intracellular esterases to an oxidative-sensitive form, dichlorodihydrofluorescein (H 2 -DCF). In the cytosol, oxidation of H 2 -DCF leads to a fluorescent compound, dichlorofluorescein (DCF), whose fluorescence intensity is proportional to intracellular ROS (28).
This fluorescent dye was used to determine ROS release in HL-60 cells, untreated or treated with oxidant agents such as (Dox, VD 3 and EB1089). Briefly, After treatment with oxidant agents described above, HL-60 cells were washed and re-suspended at 10 6 cells/mL in RPMI 1640 without FCS and phenol red. Then, 10 µM H 2 -DCFDA probe was added to each plate at a final volume of 2 mL. Cells were incubated for 45 minutes at 37 ºC in the dark. A second wash was made before the fluorescence reading using spectrometer was performed at the optimum wavelengths of 488 nm (excitation λ ex ) and 516 nm (emission λ em ). Results, obtained directly in arbitrary fluorescence units (AFU), were expressed as the percentage of control cells (100%). The percentages of fluorescent signal and of autofluorescence intensity were calculated according to the ratio [(AFU treated cells)/(AFU control cells)] × 100.
Determination of Cell Differentiation
HL-60 cell differentiation was assessed by nitroblue tetrazolium reduction assay (NBT). This assay is based on the ability of mature cells (differentiated cells) to reduce tetrazolium salts into formazan beads due to superoxide anions they produce upon stimulation with 12-0-tetradecanoyl-phorbol-13-acetate (TPA) (Sigma). To measure the NBT reduction, 2 × 10 5 cells were harvested by two centrifugations and incubated with 200 µL solution containing RPMI 1640, FCS, 1% NBT (Sigma) and 100 nM TPA for 30 min at 37 ºC in the dark. Then, cells were examined by optical microscopy. The percentage of purplish cells, indicative of formazan beads presence was assessed in comparison with untreated cells. At least 300 cells were counted for each experiment.
Statistical Analysis
All data, presented as mean ± SD were obtained from at least three independent experiments. Significant differences were determined using the Student's t-test and p<0.05 ; p<0.001 were considered to indicate significant differences.
Results
Emission Spectra of Native Cellular Fluorescence
The HL-60 living cells autofluorescence was analyzed using the UV laser microspectrofluorometry in a defined spectral range (365-580 nm). The distribution of autofluorescence image and spectra within a control HL-60 cell were presented on Figures 1A and 1B . Localization and emission intensity of autofluorescence considerably varies and different emission spectra were obtained. Although the observed variability, the emission spectra from any cell compartment, show equivalent profiles with a maximum emission at 455 nm ( Figure 1B ). Spectral shapes from HL-60 cells appear equivalent to those from another human leukemic K562 cell line already described (11).
Influence of VD 3 and EB1089 on Both Cellular Autofluorescence and Oxidative Stress
The Figure 2 presents the mean autofluorescence spectra of control and treated HL-60 cells in presence of different drug concentrations: VD 3 (1, 10, 100 nM) or EB1089 (0.1, 1 and 10 nM). A decrease in autofluorescence emission intensity was observed in cells treated with both molecules that could be attributed to the oxidation of the coenzyme NAD(P)H into NAD(P) + . To validate this hypothesis, UV molecular absorptions (260 nm and 340 nm) were analyzed in untreated-and treated-cells. O.D. values at 340 nm, specific of NAD(P)H, were 0.032, 0.016 and 0.014 for control, 10 nM EB1089-and 100 nM VD 3 -treated cells, respectively. In these treatment conditions, O.D. values at 260 nm were 0.186, 0.184 and 0.181, that do not show a significant modification of the total amount of both NAD(P) + and NAD(P)H. This result agrees with a decrease of NAD(P)H/NAD(P) + ratio during EB1089 and VD 3 treatments.
The dose-dependant decrease in autofluorescence reaches 2.5 and 2.8 factors in presence of 100 nM VD 3 , (Figure 2A ) or 10 nM EB1089 ( Figure 2B ), respectively. These two agents show significant effects from 10 nM VD 3 and 0.1 nM EB1089 concentrations (p<0.05). In order to check whether these autofluorescence variations induced by these above agents are associated to modifications of spectral profiles, a normalization of the mean spectra was made. A weak spec-
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Bondza-Kibangou et al. tral shift appears in 100 nM VD 3 -treated cells versus control ( Figure 2C ). Likewise, this shift seems to be more important than VD 3 in 10 nM EB1089-treated cells ( Figure 2D) , with emission maxima 463 nm (versus 455 nm for control cells). On the one hand, the NAD(P)H molecule has been described to be oxidized into NAD(P) + during a short exposure to Dox, VD 3 or EB1089, resulting in autofluorescence decrease. On the other hand, it has been well described that some differentiation inducing agents such as VD 3 or its analog EB1089 displayed oxidant features and consequently cause ROS release (23, 29). Our results showed that cellular autofluorescence emission is highly sensitive to oxidative stress. In that case, a significantly ROS release and decrease in this emission was observed in VD 3 and EB1089-treated cells during 72 h.
Based on these positive outcomes, we attempted to study the ability of differentiating agents VD 3 and its analog EB1089 to induce ROS release after 72 hours, in parallel with their effects on intracellular autofluorescence (Table I) . H 2 O 2 , a well known agent for its oxidative properties, has been used as a positive marker of oxidative stress. Evaluation of ROS was performed by fluorescent dye H 2 DCFDA whose fluorescence intensity was expressed in percentage: [AFU (treated cells)/AFU (control cells)] × 100 (see Materials and Methods).
The results indicated that a significantly increase in the ROS release (p<0.05) was observed in a dose-dependent manner with VD 3 and EB1089 compared to control (Table I) .
Modulation of VD 3 and EB1089 by Dox
We have previously shown that 1 µM Dox induced oxidative stress after 4 hours of incubation on K562 cells (11). This condition corresponds to an important ROS release and induces a significant decrease in autofluorescence, which confirms the susceptibility of autofluorescence to oxidative stress.
In this study, we investigated a possible additive effect of Dox and either VD 3 or EB1089 to induce oxidative stress. Dox modulates the oxidative stress induced by 1 nM VD 3 and 0.1 nM EB1089. Indeed, the association of Dox with these drugs concentrations above strongly decreases the intensity of cellular autofluorescence and induces a significant ROS release (p<0.05) versus VD 3 -and EB1089-treated cells, as indicated in the Table II .
Modulation of VD 3 and EB1089 by Antioxidant Agents
Since cellular autofluorescence was sensitive to oxidative stress, we have studied the effects of NAC (10 mM), CAT (2000 U/mL) and SOD (50 U/mL) antioxidants on this phenomenon. Table III shows both the cellular autofluorescence (% fluorescence intensity) and the ROS release after 72 hours, obtained from VD 3 or EB1089 treated cells, associated or not with NAC, CAT, SOD antioxidants. Cells were pre-treated 1 hour with each antioxidant agent before addition of VD 3 or EB1089. The results showed that autofluorescence intensity was not completely restored up to the level of untreated cells when antioxidants were associated with VD 3 or EB1089. Under these experimental conditions, autofluorescence emission was equivalent or slightly increased (p<0.05 for EB1089 and SOD co-treatment) and (p<0.05 for VD 3 and CAT co-treatment), as compared with EB1089 or VD 3 respective treatments without any antioxidant.
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This effect of antioxidants was accompanied with a decrease in ROS release induced by VD 3 and EB1089. Although the 3 antioxidants used alone are able to induce a moderate ROS generation compared to control, NAC, SOD and CAT partially abrogate ROS generated by VD 3 and EB1089 (p<0.05), suggesting a protective role of these antioxidant agents against latter VD 3 and EB1089-induced cytotoxicity (Table III) . It is noteworthy to notice that lower concentrations of antioxidants used alone which did not decrease autofluorescence emission, also has no protective effect on ROS release induced by either VD 3 or EB1089 (data not shown).
Knowing that VD 3 and EB1089 possess both pro-oxidant and differentiating activities, the following results have attempted to describe a potential relation between these effects. VD 3 and EB1089-induced differentiation of HL-60 cells into monocytic lineage was studied by nitroblue tetrazolium assay (NBT) and both CD14 gene and protein expressions, a specific monocyte marker. The concentrations of 100 nM VD 3 and 10 nM EB1089 are able to induce monocytic differentiation and growth arrest after 72 h exposure. Figure 3 showed percentage of differentiated cells ( Figure 3A ) and the fluorescence intensity of H 2 -DCFDA dye, as indicator of ROS release in VD 3 -and EB1089-treated cells ( Figure 3B ), after 24, 48 and 72 h of incubation.
These two drugs induced an increase in number of differentiated cells in a time dependant manner.
The kinetic comparisons of cell differentiation and ROS release show that 100 nM VD 3 or 10 nM EB1089 induce a small amount of ROS after 24 h, while the percentage of differentiated cells significantly increased at the same time. Moreover, an expression of monocytic CD14 gene was observed from 6 h treatment with either 100 nM VD 3 or 10 nM EB1089 (data not shown), whereas ROS release did not occur significantly before 24 h. HL-60 differentiation was abrogated by protein kinase C inhibitor GF109203x (5 µM) which markedly decreased monocytic CD14 marker expression in VD 3 and EB1089-treated cells, from 11% and 19% respectively, to less than 1% in both cases. This inhibition of myelomonocytic differentiation has no effect on ROS activation and release. Taken together, we can conclude that although the induction of differentiation by VD 3 precedes the onset of ROS generation, these two phenomena are not causally related.
Discussion
Cellular autofluorescence of HL-60 cells and its modifications under oxidative stress conditions have been studied using a laser microspectrofluorometry, under UV excitation (λ= 363 nm). Different spectra from unique HL-60 cell show an important intracellular variability of emission intensities. In terms of spectrum profile, a high intracellular and intercellular reproducibility were found. This spectral profile was equivalent to other cell lines (human breast MCF-7 cancer cells and erythroleukemic K562 cells). Previous studies had suggested that most, if not at all, of the autofluorescence arises from intracellular coenzymes such as NAD(P)H under UV excitation (1, 4) . Moreover, an important NAD(P)H pool comes from the mitochondrial compartment. Indeed, highest concentrations of these compounds would be expected in mitochondria. The NAD(P)H oxidation into NAD(P) + in mitochondria is followed by the hydrolysis of NAD(P) + to ADP ribose and the release of both nicotinamide and Ca 2+ . This results in a irreversible decrease in NAD(P)H intramitochondrial pool (30). The intracellular autofluorescence appears to be restricted in the cytoplasm compartments which can be attributed to organelles and particularly to mitochondria (2). These authors have also suggested an involvement of other organelles such as lysosomes which contain the autofluorescent age pigment lipofuscin. Consequently, we suggest that another NAD(P)H pool outside mitochondria could partly contribute to the autofluorescence phenomenon.
Several studies have shown evidence that VD 3 displays prooxidant features against different cancer cell lines. However, the oxidant/antioxidant status of VD 3 remains unclear since other authors have demonstrated antioxidant properties of VD 3 against various stress stimuli including H 2 O 2 (31) or in association with some plant-derived polyphenol compound carnosic acid (CA) (32). One explanation of this discrepancy could be due to the origin of cellular type and their sensitivity to VD 3 .
In vivo and in vitro anticancer activity of VD 3 has been commonly attributed to its direct cytostatic and cytotoxic effects on cancer cells. Most of the above effects should be due to a massive involvement of ROS in human breast MCF-7 cancer cells, which confer to VD 3 and its analog oxidant features (23, 29). Our results showed that for VD 3 -and EB1089-treated cells, a significant decrease in the autofluorescence intensity has been observed. This decrease can be assigned to NAD(P)H oxidation and may be correlated to free radicals release. One plausible explanation to appraise the relationship between autofluorescence variations and ROS release was described by Gendron et al. (33) . These authors have clearly demonstrated that mitochondrial coenzyme NAD(P)H was oxidized and depleted during Fas-and Ceramide-induced programmed cell death (apoptosis) in Jurkat cells. Besides, this decrease and depletion in NAD(P)H was preceded by loss of mitochondrial transmembrane potential and appeared well before any enhanced generation of ROS and caspase activation.
The comparison of autofluorescence intensity between control cells and 1 mM H 2 O 2 -treated cells displays a residual fluorescence emission, as seen in Tables I and III . This component is not assigned to NAD(P) + with a maximum emission at 440 nm (spectra not shown), which suggests the possible involvement of another molecule which can be responsible for autofluorescence emission. A second suggestion could be proposed to account for this residual fluorescence: the treatment by hydrogen peroxide would not oxidize all the compartments within the cell. Several sites would not be accessible by hydrogen peroxide and still remain fluorescent.
The modulation of autofluorescence and oxidative stress by Dox was also investigated. Dox causes a significant decrease in HL-60 cellular autofluorescence intensity, as previously described in our previous data (11). When cells were cotreated with Dox and either VD 3 or EB1089, autofluorescence intensity was more decreased than for isolated treatment (in parallel with a tremendous ROS release) (Table II ). It has been described that VD 3 synergistically enhanced the susceptibility of MCF-7 cancer cells to Dox and menadione (16). It could be possible that additive effect obtained with EB1089 and Dox may result from the efficacy of EB1089, a novel VD 3 analog which could more easily interact with Dox to induce pro-oxidant activities. It is also noteworthy that pre-treatment of cancer cells with VD 3 or EB1089 selectively increased their susceptibility to anticancer cytokines via ROS generation (22) or to all-trans-retinoic acid (ATRA) (34). Such combinations may provide useful therapeutic perspectives in the treatment of a large variety of cancers.
Antioxidant agents such as NAC, SOD and CAT are important in cellular defenses against the oxidative damage caused by anticancer drugs. NAC is thought to act by raising intracellular concentrations of GSH and by direct scavenging of ROS (22, 28) . SOD represents the first line of defense of the cellular antioxidant system against the oxidative damage mediated by superoxide radicals, removing them by catalyzing the dismutation of two superoxide radicals to yield hydrogen peroxide (H 2 O 2 ). This ROS is finally removed from the circulation and transformed into H 2 O and oxygen by CAT (16). In HL-60 cells, we showed that addition of antioxidant agents (NAC, SOD or CAT) almost abolished the VD 3 -and EB1089-induced ROS release, even after a long incubation time. This confirms that one potential mechanism of action of VD 3 and EB1089, as anticancer agents is based on ROS induction (23). However, these antioxidants used in combination with VD 3 or EB1089 were unable to totally restore autofluorescence intensity close to values of untreated cells. Two hypotheses could be suggested: (i) First, VD 3 and EB1089 could directly oxidize NAD(P)H, into NAD(P) + , leading to ROS generation. The antioxidant supplementation would be sufficient to block ROS, but not the upstream NAD(P)H oxidation. (ii) Second, other factors could be oxidized during the disturbance of mitochondrial respiratory chain and interact with autofluorescence via NAD(P)H pool. Finally, our results showed a pro-oxidative tendency induced by antioxidant molecules NAC, SOD and CAT, when used alone both on ROS release and autofluorescence decrease. Under our experimental conditions that allowed a decreased VD 3 -(or EB1089)-ROS release, the enzyme activity (CAT, SOD) or NAC concentration were also able to decrease autofluorescence emission, attributed to NADH oxidation into NAD + . These conditions could interfere through the regulation of other antioxidant defense systems. Such a phenomenon has been previously highlighted by , who noticed that the antioxidant melatonin, under certain conditions (aqueous system, concentrations) could lead to pro-oxidant activity both on lipids and proteins in erythrocyte cell membrane.
In conclusion, the cellular autofluorescence appears to be located in cytoplasmic compartment, inside and outside mitochondria. Anticancer agents VD 3 and EB1089 markedly decrease the emission intensity, which is attributed to oxidation of NAD(P)H pools. The relationship between NAD(P)H oxidation and the followed ROS release may account for VD 3 -and EB1089-induced cytostatic and cytotoxic effects.
